Regional Meetings 2017-2018

Second Opinion: New and Emerging Treatment Strategies in the Management of Recurrent Ovarian Cancer

Research To Practice is pleased to offer practicing oncologists and other allied healthcare professionals throughout the United States the opportunity to attend an educational activity focused on the management of ovarian cancer. Each session in this regional series will include a blend of didactic minipresentations, video case presentations from clinicians in practice, interactive polling of the audience using keypad devices and follow-up discussion and audience Q&A.

If you are interested in hosting a session at your institution, please contact our Meeting Services department at or call (800) 233-6153.

Please click here to learn more about our Breast Cancer series.

Schedule of Events:

Friday, January 12, 2018
12:00 PM – 1:00 PM
Education program

Don S Dizon, MD
Watson Clinic Cancer and Research Center
Lakeland, Florida

Lunch buffet will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Wednesday, January 17, 2018
6:00 PM
Registration and dinner
6:30 PM – 7:30 PM
Education program

Don S Dizon, MD
Ironwood Cancer & Research Center
Mesa, Arizona

Dinner buffet will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
There is no registration fee for these events. However, preregistration is advised, as seating is limited.

Each 1-hour session will include 4 topic modules focused on the current management of biologically defined subsets of ovarian cancer (OC) and emerging research information on novel agents and strategies under active investigation. Each module will employ an identical format and include:

  • Audience Polling Using Keypad Devices
  • Display of Steering Committee Responses to Related Clinical Questions
  • Faculty Review of Select Data Sets
MODULE 1: Overview of the Management of Recurrent Disease MODULE 2A: Biologic Basis for the Use of PARP Inhibitors and BRCA Testing MODULE 2B: PARP Inhibition as a Therapeutic Strategy MODULE 3: Novel Investigational Agents

Each session will conclude with a 5-minute Q&A segment


Michael Birrer, MD, PhD
Director, UAB Comprehensive Cancer Center
University of Alabama at Birmingham
Birmingham, Alabama

Robert L Coleman, MD
Professor and Vice Chair
Clinical Research
Ann Rife Cox Chair in Gynecology
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Don S Dizon, MD
Director, Women’s Cancers
Lifespan Cancer Institute
Director, Medical Oncology
Rhode Island Hospital
Associate Professor of Medicine
Alpert Medical School of Brown University
Providence, Rhode Island

Thomas J Herzog, MD
Paul and Carolyn Flory Professor
Deputy Director, UC Cancer Institute
Vice Chair, Quality and Safety
Department of Obstetrics and Gynecology
University of Cincinnati
Cincinnati, Ohio

Ursula A Matulonis, MD
Medical Director and Program Leader
Gynecologic Oncology Program
Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
Bradley J Monk, MD
Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona
College of Medicine - Phoenix
Creighton University
School of Medicine at St Joseph’s Hospital
Phoenix, Arizona

Kathleen Moore, MD
Jim and Christy Everest Endowed Chair in Cancer Research
Director, Oklahoma TSET Phase I Program
Stephenson Cancer Center
Associate Professor, Section of Gynecologic Oncology
Director, Gynecologic Oncology Fellowship
Department of Obstetrics and Gynecology
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

Angeles Alvarez Secord, MD, MHSc
Department of Obstetrics and Gynecology
Division of Gynecologic Oncology
Duke Cancer Institute
Durham, North Carolina

Project Chair

Neil Love, MD
Research To Practice
Miami, Florida

Target Audience:
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of ovarian cancer (OC).

Learning Objectives:

  • Evaluate current standard therapies and emerging treatment options, and use this information to appropriately select and sequence therapeutic approaches for patients with recurrent OC.
  • Describe the rationale for targeting angiogenic pathways in gynecologic cancers, and consider the role of the anti-VEGF antibody bevacizumab in the initial and long-term treatment of advanced OC.
  • Use available guidelines and consensus statements to inform the selection of validated genetic testing platforms for patients with OC, and employ the resulting information to guide treatment planning and genetic counseling for these individuals.
  • Understand the rationale for the investigation of PARP inhibitors as monotherapy for patients with BRCA mutation-positive advanced OC, and use this information to inform protocol and nonresearch treatment options for these individuals.
  • Appreciate the FDA approval of rucaparib for patients with refractory advanced OC, and safely integrate this agent into clinical management as appropriate.
  • Evaluate Phase III evidence supporting the use of PARP inhibitor maintenance therapy for patients with recurrent, platinum-sensitive OC with and without BRCA mutations who are responding to platinum-based chemotherapy.
  • Recognize the mechanisms of action, emerging efficacy data and toxicity profiles of investigational agents and immunotherapeutic strategies for the treatment of OC, and counsel appropriately selected patients about the availability of ongoing clinical trials.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech BioOncology, ImmunoGen Inc, Myriad Genetic Laboratories Inc and Tesaro Inc.